VRCA
Verrica Pharmaceuticals Inc

2,310
Mkt Cap
$110.56M
Volume
14,346.00
52W High
$9.82
52W Low
$3.28
PE Ratio
-2.01
VRCA Fundamentals
Price
$6.66
Prev Close
$6.91
Open
$6.94
50D MA
$7.81
Beta
0.50
Avg. Volume
149,100.90
EPS (Annual)
-$14.78
P/B
-3.85
Rev/Employee
$106,563.38
Loading...
Loading...
News
all
press releases
Verrica Pharmaceuticals (NASDAQ:VRCA) Downgraded to Hold Rating by Wall Street Zen
Wall Street Zen cut shares of Verrica Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Saturday...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Verrica Pharmaceuticals (VRCA) Upgraded to Strong Buy: Here's Why
Verrica Pharmaceuticals (VRCA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Zacks·8d ago
News Placeholder
New Strong Buy Stocks for February 2nd
LUV, VRCA, CVLT, FINW and SDVKY have been added to the Zacks Rank #1 (Strong Buy) List on February 2, 2026.
Zacks·8d ago
News Placeholder
Sovran Advisors LLC Trims Holdings in Verrica Pharmaceuticals Inc. $VRCA
Sovran Advisors LLC trimmed its holdings in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA - Free Report) by 90.2% in the 3rd quarter, according to the company in its most recent filing with the...
MarketBeat·12d ago
News Placeholder
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Short Interest Update
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA - Get Free Report) saw a significant drop in short interest in December. As of December 31st, there was short interest totaling 292,263 shares, a drop of...
MarketBeat·23d ago
News Placeholder
Verrica Pharmaceuticals (NASDAQ:VRCA) Upgraded to "Buy" at Wall Street Zen
Wall Street Zen raised shares of Verrica Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday...
MarketBeat·24d ago
News Placeholder
How Much Upside is Left in Verrica Pharmaceuticals (VRCA)? Wall Street Analysts Think 97.11%
The mean of analysts' price targets for Verrica Pharmaceuticals (VRCA) points to a 97.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·29d ago
News Placeholder
Short Interest in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Decreases By 26.2%
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA - Get Free Report) was the recipient of a significant decrease in short interest in December. As of December 15th, there was short interest totaling 380,561...
MarketBeat·1mo ago
News Placeholder
Armistice Capital LLC Increases Stock Holdings in Verrica Pharmaceuticals Inc. $VRCA
Armistice Capital LLC boosted its stake in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA - Free Report) by 3.7% in the second quarter, according to its most recent filing with the Securities and Exchange...
MarketBeat·2mo ago
News Placeholder
Verrica Pharmaceuticals (NASDAQ:VRCA) CEO Jayson Rieger Purchases 94,311 Shares
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA - Get Free Report) CEO Jayson Rieger acquired 94,311 shares of the business's stock in a transaction that occurred on Tuesday, November 25th. The shares were...
MarketBeat·3mo ago
<
1
2
...
>

Latest VRCA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.